articleThe LancetApr 1, 2006BRONZE OA

Sustained efficacy up to 4·5 years of a bivalent L1 virus-like particle vaccine against human papillomavirus types 16 and 18: follow-up from a randomised control trial

DMDiane M. HarperELEduardo L. FrancoCMCosette M. WheelerAMAnna‐Barbara MoscickiBRBarbara Romanowski

Dartmouth College · McGill University · +8 more institutions

PubMed
Indexed incrossrefpubmed

Abstract

No abstract available for this paper.

Citation impact

1,636
total citations
FWCI
160.82
Percentile
100%
References
30
Citations per year

Authors

10

Topics & keywords

Topics
Keywords
  • Bivalent (engine)
  • Medicine
  • Human papillomavirus
  • Human papillomavirus vaccine
  • Randomized controlled trial
  • Virus-like particle
  • Vaccine efficacy
  • Virology
UN Sustainable Development Goals
  • Good health and well-being
No related works found for this paper.

Funding